StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Equity method investment in Galapagos NV / Lakefront by Quarter

Equity method investment in Galapagos NV / Lakefront Biotherapeutics NV — Fair value carrying amount ($M) ($M)

QuarterlyAnnual

Gilead Sciences Equity method investment in Galapagos NV / Lakefront: $500M in Q2 2026.

Latest, Q2 2026
500
Period ended Jun 30, 2026
Change on a year earlier
–
History
23 quarters
Since Q4 2018
Sources
21
Documents cited below

Where the Q2 2026 figure comes from

“|| Equity method investment in Lakefront Biotherapeutics NV (“Lakefront”) (formerly known as Galapagos NV) – fair value option | 500 | 551”

Source: Form 10-Q (gild-20260630.htm, filed 2026-08-06) ↗

Reported in Form 10-Q / 10-K Note 3 Fair Value & Note 4 Equity Securities.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEquity method investment in Galapagos NV / Lakefront Biotherapeutics NV — Fair value carrying amount ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026500–Form 10-Q (gild-20260630.htm, filed 2026-08-06) ↗
Q1 2026Mar 31, 2026504–Form 10-Q (gild-20260331.htm, filed 2026-05-07) ↗
Q4 2025Dec 31, 2025551+19.3%Form 10-Q (gild-20260630.htm, filed 2026-08-06) ↗
Q3 2025Sep 30, 2025570–Form 10-Q (gild-20250930.htm, filed 2025-11-07) ↗
Q4 2024Dec 31, 2024462–Form 10-K (gild-20251231.htm, filed 2026-02-24) ↗
Q3 2023Sep 30, 2023571-18.8%Form 10-Q (gild-20230930.htm, filed 2023-11-07) ↗
Q2 2023Jun 30, 2023682-27.1%Form 10-Q (gild-20230630.htm, filed 2023-08-04) ↗
Q1 2023Mar 31, 2023639-38.9%Form 10-Q (gild-20230331.htm, filed 2023-05-03) ↗
Q4 2022Dec 31, 2022736-20.9%Form 10-Q (gild-20230930.htm, filed 2023-11-07) ↗
Q3 2022Sep 30, 2022703-20.2%Form 10-Q (gild-20220930.htm, filed 2022-11-02) ↗
Q2 2022Jun 30, 2022935-19.7%Form 10-Q (gild-20220630.htm, filed 2022-08-08) ↗
Q1 2022Mar 31, 20221,046-19.7%Form 10-Q (gild-20220331.htm, filed 2022-05-04) ↗
Q4 2021Dec 31, 2021931-43.5%Form 10-K (gild-20221231.htm, filed 2023-02-22) ↗
Q3 2021Sep 30, 2021881-62.7%Form 10-Q (gild-20210930.htm, filed 2021-11-03) ↗
Q2 2021Jun 30, 20211,164-64.5%Form 10-Q (gild-20210630.htm, filed 2021-08-05) ↗
Q1 2021Mar 31, 20211,302-60.7%Form 10-Q (gild-20210331.htm, filed 2021-05-06) ↗

Cite this data

StockData. (2026). Gilead Sciences Equity method investment in Galapagos NV / Lakefront ($M), quarterly Q4 2018–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/eq-inv-galapagos

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.